Subscribe to our Newsletters !!
The delicate, slend
Saint-Germain-en-Laye, France – October 5, 2021
Scientists have developed a chemical compound that
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Drug firm Alembic Pharmaceuticals on Monday said i
BioChromato report how their ionRocket sample prep
Mycelial cultures were obtained from fragments of
AMSBIO has launched STEM-CELLBANKER® EX – a next generation cryopreservation product that eliminates the need for the traditional washing steps required in cell therapy product development.
Rapid developments in cell, tissue, and gene therapies over the last decade have redefined what a cell therapy can be. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. However, the development of a cell therapy using a process that includes the washing out of the cryopreservation solution is not only inconvenient but can result in loss of cells and lower cell viability. Due to its unique formulation, STEM-CELLBANKER® EX eliminates the need for this step.
Assisting easier implementation in a clinical environment – STEM-CELLBANKER® EX is a chemically defined cryopreservation media solution that only includes components registered as inactive ingredients that have already been approved for intravenous administration. Manufactured under strict US, EU and PIC/S GMP guidelines – STEM-CELLBANKER® EX is a serum free and animal component free, sterile DMSO-containing solution optimized for cryopreserving human cells, tissues and organoids.
Proven to maintain cell pluripotency, normal karyotype, and proliferation ability post-thaw – STEM-CELLBANKER® EX delivers consistently higher cell viability and cell recovery than other cryopreservation media.
For further information please visit https://www.amsbio.com/stem-cell-cryopreservation-ex/ or contact AMSBIO on+44-1235-828200 / +1-617-945-5033 / firstname.lastname@example.org.